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REVIEW ARTICLE

COVID-19 and Older Adults: What We Know
Zainab Shahid, BS,*† Ricci Kalayanamitra, BS,‡§ Brendan McClafferty, BS,*
Douglas Kepko, BS,* Devyani Ramgobin, BS,¶ Ravi Patel, DO,∥
Chander Shekher Aggarwal, MBBS,** Ramarao Vunnam, MD,∥ Nitasa Sahu, MD,∥
Dhirisha Bhatt, MD,∥ Kirk Jones, PharmD,†† Reshma Golamari, MD,∥ and Rohit Jain, MD∥

Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), a novel virus that causes COVID-19 infection, has
recently emerged and caused a deadly pandemic. Studies
have shown that this virus causes worse outcomes and a
higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney
disease (CKD). A signiﬁcant percentage of older American
adults have these diseases, putting them at a higher risk of
infection. Additionally, many adults with hypertension, diabetes, and CKD are placed on angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II receptor
blockers. Studies have shown that these medications
upregulate the ACE-2 receptor, the very receptor that the
SARS-CoV-2 virus uses to enter host cells. Although it has
been hypothesized that this may cause a further increased
risk of infection, more studies on the role of these medications in COVID-19 infections are necessary. In this review,
we discuss the transmission, symptomatology, and mortality of COVID-19 as they relate to older adults, and possible treatments that are currently under investigation. J Am
Geriatr Soc 68:926-929, 2020.
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lusters of pneumonia cases occurring in the city of
Wuhan in December 2019 led to the eventual identiﬁcation of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2).1,2 Through an epidemiological investigation, the Chinese government narrowed down the origin of
the virus to the Huanan seafood market in Wuhan. The
viral sequence had a 96% similarity to a bat coronavirus,
and, with no evidence of bat-to-human transmission, it was
hypothesized that the virus spread to humans through an
intermediate host.1,3 Genomic sequence studies from
Malaysia later suggested that the intermediate hosts were
pangolins that were smuggled into China from Malaysia
and sold at the Huanan seafood market.4 The subsequent
human-to-human spread set off what later turned into a
pandemic.
The World Health Organization (WHO) declared
SARS-CoV-2 as a pandemic on March 11, 2020. As of
March 23, 2020, at 13:25 EST, there were 362,019 conﬁrmed cases of SARS-CoV-2 reported from 168 different
countries, with 15,488 deaths and an overall projected case
fatality rate (CFR) of 4.3%.5 The Centers for Disease Control and Prevention (CDC) reported that although individuals older than age 65 comprise 17% of the total
population in the United States, they make up 31% of
COVID-19 infections, 45% of hospitalizations, 53% of
intensive care unit admissions, and 80% of deaths caused
by this infection.6 This suggests that older individuals are
more likely to get COVID-19 and have worse outcomes
compared with the general population.

PATHOPHYSIOLOGY
SARS-CoV-2 spreads via direct, contact, and aerosol transmission of respiratory droplets and has a median incubation
period of 5.1 days.7,8 A recent study found that SARSCoV-2 lasts in aerosols for up to 3 hours and remains
detectable for up to 72 hours on plastic and stainless-steel
surfaces, 24 hours on cardboard, and 4 hours on copper.9
Another possible mode of transmission of SARS-CoV-2
may be through fecal-oral transmission. In a study done
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on 10 pediatric patients with SARS-CoV-2 infections, 8 continuously tested positive for the virus on rectal swabbing,
despite testing negative on nasopharyngeal swabs.10 Given
these ﬁndings, patients who test negative on a nasopharyngeal swab could potentially still have an active infection.
The current proposed mechanism for cell entry is via
the angiotensin-converting enzyme-2 (ACE-2) receptor
found in the lungs, endothelium, heart, kidneys, and gastrointestinal system.1 Spike proteins on the exterior of SARSCoV-2 anchor the virus to ACE-2 receptors on cells in the
lower respiratory tract. This speciﬁc mechanism of action
may propose a higher risk of infection for older adults.
According to the CDC, 63.1% of adults older than age
60 have hypertension, 38% of people older than 65 years
have chronic kidney disease (CKD), and 26.8% of adults
older than age 65 have diabetes.11-13 Many of these patients
use ACE inhibitors and angiotensin-receptor blockers
(ARBs) that upregulate the ACE-2 receptor.14 Thus it is
hypothesized that older individuals with such comorbidities
may have an elevated risk of and experience a more severe
course of infection with SARS-CoV-2.

CLINICAL PRESENTATION
The most common presenting symptoms in the general population are fever (98%), cough (76%), dyspnea (55%), and
myalgias or fatigue (up to 44%).15,16 These symptoms are
also common in older adults; one study on 21 critically ill
patients with SARS-CoV-2 infection, with a mean age of
70 years, found that the most common presenting symptoms were shortness of breath (76%), fever (52%), and
cough (48%). Up to 86% of older adults presented with
comorbidities, and the most signiﬁcant ones were CKD
(48%), congestive heart failure (43%), chronic obstructive
pulmonary disease (COPD) (33%), and diabetes (33%).17
Most older adults have some form of organ damage
occurring due to SARS-CoV-2 including acute respiratory
disease syndrome (71%), acute kidney injury (20%), cardiac injury (33%), and liver dysfunction (15%), and 67%
required vasopressor support for treatment.17 In all age
groups, chest computed tomography imaging of patients
with SARS-CoV-2 revealed ground glass opacities (GGOs)
(87%), mixed GGOs and consolidation (65%), vascular
enlargement (72%), and traction bronchiectasis (53%).
Among these, lesions had peripheral distribution (87.1%),
bilateral lung involvement (82.2%), lower lung predominance (54.5%), and multifocality (54.5%).18 Comparatively, chest radiograph ﬁndings in older adults showed
bilateral reticular-nodular opacities (58%), GGOs (48%),
pleural effusions (about 33%), peribronchial thickening
(about 25%), and focal consolidations (20%).17

MORTALITY IN OLDER ADULTS
The mortality of the SARS-CoV-2 pandemic in older adults
has been striking. According to the joint WHO-China factﬁnding mission, the overall CFR of 17.3% in January
decreased to .7% in February, whereas the CFR in adults
older than age 80 had increased to 21.9%.19 Another analysis of 72,314 cases indicated an overall CFR of 2.3%, but
a CFR of 8% in patients aged 70 to 79 years and 14.5% in
patients older than age 80.20 A report on 355 patients with
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SARS-CoV-2 found that patients who died had an average
age of 79.5 years.21 Another report on 4,226 cases in the
United States indicated a CFR less than 1% in patients
younger than age 54 but a CFR of 3% to 11% in patients
aged 65 to 84 and 10% to 27% in patients older than age
85. More than 80% of deaths among adult patients
occurred in those older than age 65.6 Most of the fatal cases
to date have involved older adults and patients with
comorbidities.20,22
Many older adults in the United States have cardiovascular disease (17%), diabetes (26.8%), hypertension
(63.1%), COPD (23.7%), and CKD (38%).13,23-26 An analysis by the joint WHO-China fact-ﬁnding mission found that
patients older than age 60 and those with comorbidities had
the highest risk for severe disease and death. The CFR in
patients without comorbidities was 1.4%, whereas the CFR
was 13.2% for patients with cardiovascular disease, 9.2%
for patients with diabetes, 8.4% for patients with hypertension, 8% for patients with chronic respiratory disease, and
7.6% for patients with cancer.19 One study on 46 fatal cases
of SARS-CoV-2, in which 84% of patients were older than
age 60, found that diabetes is likely associated with increased
mortality.15 Another study on critically ill older patients with
SARS-CoV-2 found that 86% of patients had comorbid conditions such as CKD, congestive heart failure, COPD, and
diabetes.17 This likelihood of having multiple comorbidities
places older adults at an even greater risk of increased mortality from SARS-CoV-2.

TREATMENT
SARS-CoV-2 can be described as a superspreading event that
has a rapidly early growth that is then sustained.27 The best
precautions are maintaining regular hand hygiene (because
viral stool shedding and viability on surfaces can last from
2 hours to 9 days), decreasing social contact, and, for
healthcare workers, wearing personal protective equipment.27-29 The reproductive number (R0) for the virus
dropped from 3.86 to .32 in a 5-week period once these precautions were taken in China.27 For patients with COVID-19
infection, treatment is focused on supportive care. Although
there is currently no FDA-approved treatment, many medications are being studied for effectiveness against SARS-CoV-2.
Chloroquine, a drug approved by the Food and Drug
Administration (FDA) for malarial and autoimmune diseases, has shown efﬁcacy against SARS-CoV-2 in vitro. It
works by increasing the endosomal pH required for viralcell fusion and by interfering with the terminal glycosylation of ACE-2.30 More than 20 clinical trials are currently
ongoing in China to assess chloroquine as a possible treatment for COVID-19, and the State Council of China has
stated that chloroquine has demonstrated marked efﬁcacy
in treating COVID-19–associated pneumonia in multicenter
clinical trials conducted in China.31,32 A nonrandomized
clinical trial on 20 patients with conﬁrmed COVID-19
infection showed that after a daily dose of 600 mg hydroxychloroquine, a less toxic derivative of chloroquine,
57.1% of patients were virus free in 6 days.33
Another drug with promising results is remdesivir, an
intravenous drug that inhibits SARS-CoV-2 replication
through premature termination of viral RNA. Remdesivir is
a non–FDA-approved investigational drug that has been
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effective against COVID-19 in vitro and has been used on
an expanded access, or compassionate use, basis in the
United States.34,35 In one case, the patient received
remdesivir on day 7 of hospitalization due to his worsening
condition, and he subsequently had an improvement in
symptoms, no longer required oxygen supplementation,
and had no adverse effects due to treatment.36 Currently six
clinical trials for remdesivir are ongoing.37-42 There is also
currently an ongoing phase I clinical trial sponsored by the
National Institute of Allergy and Infectious Diseases testing the
safety and immunogenicity of a vaccine for SARS-CoV-2.43
There is no beneﬁt of the inﬂuenza vaccine for prevention
of SARS-CoV-2 infection, and the CDC recommends all
individuals older than age 6 months receive the inﬂuenza
vaccine to prevent inﬂuenza and unnecessary evaluation
for SARS-CoV-2.44
In conclusion, the SARS-CoV-2 pandemic has a much
higher mortality rate in older adults, and older adults who
have certain comorbidities and take ACE inhibitors or
ARBs may have a greater risk of infection and worse outcomes. Although many medications and a vaccine are currently under investigation, no FDA-approved treatments or
vaccines are available for this virus.
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